Business
Cosmo Receives CE Certification for ColonPRO EU - The Most Advanced AI Software Platform for Colonoscopy in Europe
Dublin, Ireland--(Newsfile Corp. - November 3, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN), a global leader in AI-powered healthcare and specialty pharma, today announced that ColonPRO EU, the Company’s next-generation artificial intelligence software for colonoscopy, has received CE certification. Following FDA clearance in the United States, this certification brings to Europe the most advanced AI-assisted colonoscopy platform ever developed. The system has already been used...
About this update from Cosmo Pharmaceuticals Nv
[{"type":"text","content":"Dublin, Ireland--(Newsfile Corp. - November 3, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN), a global leader in AI-powered healthcare and specialty pharma, today announced that ColonPRO EU, the Company’s next-generation artificial intelligence software for colonoscopy, has received CE certification. Following FDA clearance in the United States, this certification brings to Europe the most advanced AI-assisted colonoscopy platform ever developed. The system has already been used to support more than four million procedures worldwide.","length":540,"tagName":"p"},{"type":"text","content":"ColonPRO EU integrates four complementary AI modules that work together to support physicians through every step of colonoscopy – from detection to diagnosis, measurement, and quality assessment:","length":195,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Real-time Polyp Detection (CADe): Validated in multiple international trials, including COLO-DETECT (The Lancet Gastroenterology & Hepatology, 2024), showing an 8.3 percentage-point improvement in adenoma detection rate versus standard colonoscopy. The latest version further increases specificity, reducing false positives by 9%.","length":334,"tagName":"p"}]},{"val":[{"type":"text","content":"Real-time Polyp Characterization (CADx): Proven in the PRACTICE randomized controlled trial (The Lancet Gastroenterology & Hepatology, 2025) to safely support “diagnose-and-leave” strategies for diminutive polyps, reducing unnecessary resections without compromising safety.","length":278,"tagName":"p"}]},{"val":[{"type":"text","content":"Real-time Polyp Sizing (CADs): Introduced for the first time in ColonPRO EU, validated in the METER study (Endoscopy, 2025), achieving 85.8% accuracy in size classification and 90.8% correctness in surveillance-interval assignment per ESGE guidelines.","length":251,"tagName":"p"}]},{"val":[{"type":"text","content":"Procedure Highlights (CAQ): Newly added to automatically capture inspection times, bowel-prep scores, and caecal-intubation rates — providing objective quality metrics that allow endoscopy units to monitor performance and continuously improve outcomes.","length":252,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":1115,"olType":false},{"type":"text","content":"Together, these modules form a seamlessly integrated a...